# Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion

> **NCT06968572** · PHASE1 · RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 245 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** HSK41959

## Key facts

- **NCT ID:** NCT06968572
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-11
- **Primary completion:** 2026-03-26
- **Final completion:** 2028-05-08
- **Target enrollment:** 245 (ESTIMATED)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06968572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06968572, "Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06968572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*